| --- | --- | --- | --- | |-------|------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | Q1 FY25 Earnings | | | • Q1 FY25 Earnings Cautions Concerning Forward-Looking Statements This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ | --- | --- | |--------------------------------------------------------------------------------------|------------------------ ...

Cardinal Health (CAH) came out with quarterly earnings of $1.88 per share, beating the Zacks Consensus Estimate of $1.64 per share. This compares to earnings of $1.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.63%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $1.72 per share when it actually produced earnings of $1.84, delivering a surprise of 6.98%.Over the last four qu ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Cardinal Health Reports First Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook • Revenue decreased 4% to $52.3 billion; revenue increased 15% excluding the impact of the previously communicated large customer contract expiration • GAAP operating earnings were $568 million; GAAP diluted EPS was $1.70 • Non-GAAP operating earnings increased 12% to $625 million, driven by significant growth in Pharmaceutical and Specialty Solutions segment profit • Non-GAA ...

New facility in Boylston increases U.S. warehouse capacity and expands specialized handling capabilities DUBLIN, Ohio, Oct. 29, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the grand opening of its new distribution center in Boylston, Massachusetts, supporting its U.S. Medical Products and Distribution business. The facility provides healthcare customers in Massachusetts, New Hampshire, Rhode Island, Maine, Vermont and Eastern Connecticut with modernized operations and expanded capacity, ...

Analysts on Wall Street project that Cardinal Health (CAH) will announce quarterly earnings of $1.64 per share in its forthcoming report, representing a decline of 5.2% year over year. Revenues are projected to reach $51.26 billion, declining 6.4% from the same quarter last year. Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. Before a company announces ...

Cardinal Health, Inc. (CAH) is scheduled to report  fiscal first-quarter 2025 results on Nov. 1, before the opening bell.In the last reported quarter, the company delivered an earnings surprise of 6.98%. CAH’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 13.47%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q1 Estimates for Cardinal HealthFor the fiscal first quarter, the consensus mark for earnings is pegged at ...

Cardinal Health (CAH) closed the latest trading day at $111.92, indicating a -0.52% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.77% for the day. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq saw an increase of 0.87%. The prescription drug distributor's shares have seen a decrease of 0.58% over the last month, surpassing the Medical sector's loss of 3% and falling behind the S&P 500's gain of 4.87%. Investors ...

Cardinal Health (CAH) and T2 Biosystems recently entered into a multi-year exclusive U.S. agreement, selecting CAH as an exclusive distributor to sell T2 Biosystems’ FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx Instrument, the T2Bacteria Panel and the T2Candida Panel.Likely Trend of CAH Stock Following the NewsFollowing the announcement, shares of the company traded at $111.32 at yesterday’s closing.Cardinal Health's pharmaceutical and med ...

LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems’ FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx® ...